tadalafil has been researched along with Cardiometabolic Syndrome in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koka, S; Kukreja, RC; Xi, L | 1 |
| Cai, J; Li, CD; Shang, XJ; Wang, QQ; Wu, ZG; Xiao, YB; Zhou, CF | 1 |
| Chapple, C; Gacci, M; Gemma, L; Gravas, S; Kaplan, SA; Liaci, A; Maggi, M; McVary, KT; Morselli, S; Sebastianelli, A; Serni, S; Spatafora, P; Vignozzi, L; Zaccaro, C | 1 |
| Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
| Albano, G; Altieri, V; Castaldo, L; D'Agostino, M; Del Forno, D; Ferro, M; Giallauria, F; Lucci, R; Mancini, M; Maresca, L; Torella, G; Vigorito, C; Vitelli, A | 1 |
| Aversa, A; Bani, D; Cellai, I; Comeglio, P; Corcetto, F; Corno, C; Filippi, S; Francomano, D; Galli, A; Guasti, D; Lenzi, A; Maggi, M; Maneschi, E; Mannucci, E; Mazzanti, B; Mello, T; Morelli, A; Salvatore, G; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
| Banerjee, SK; Katare, PB | 1 |
| Kocaaslan, R; Onen, E; Otunctemur, A; Ozbek, E; Ozcan, L; Polat, EC | 1 |
| Brown, NJ; Eckhauser, AW; Hill, KD; Marney, A | 1 |
| La Vignera, S | 1 |
1 review(s) available for tadalafil and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride; Diabetes Mellitus; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Metabolic Syndrome; Piperazines; Tadalafil | 2016 |
3 trial(s) available for tadalafil and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors.
Topics: Adult; Aged; Carbolines; Erectile Dysfunction; Exercise; Humans; Male; Metabolic Syndrome; Middle Aged; Phosphodiesterase 5 Inhibitors; Tadalafil; Treatment Outcome | 2013 |
Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome.
Topics: Adult; Aged; Erectile Dysfunction; Humans; Male; Metabolic Syndrome; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Tadalafil; Testosterone | 2017 |
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbolines; Cross-Over Studies; Double-Blind Method; Female; Humans; Insulin-Secreting Cells; Male; Metabolic Syndrome; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Ramipril; Renin; Tadalafil | 2009 |
6 other study(ies) available for tadalafil and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dyslipidemias; Heart; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Phosphodiesterase 5 Inhibitors; Tadalafil; Ventricular Function, Left | 2020 |
[Low-dose PDE5 inhibitors for erectile dysfunction with subclinical metabolic syndrome].
Topics: Adult; Erectile Dysfunction; Humans; Male; Metabolic Syndrome; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Tadalafil; Young Adult | 2019 |
Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome.
Topics: Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin | 2021 |
Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model.
Topics: Amides; Animals; Carbolines; Diet, High-Fat; Enzyme Inhibitors; Male; Metabolic Syndrome; Muscle Contraction; Muscle, Smooth; Pyridines; Rabbits; rho-Associated Kinases; Signal Transduction; Tadalafil; Up-Regulation; Urinary Bladder Diseases; Urological Agents | 2014 |
Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits.
Topics: Adipose Tissue, Brown; Animals; Cell Differentiation; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Intra-Abdominal Fat; Male; Metabolic Syndrome; Mitochondria; Rabbits; Tadalafil; Uncoupling Protein 1 | 2016 |
New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome: effects of tadalafil administration.
Topics: Analysis of Variance; Antigens, CD; Antigens, CD34; Cadherins; Carbolines; Cell-Derived Microparticles; Endothelial Cells; Flow Cytometry; Humans; Immunophenotyping; Impotence, Vasculogenic; Italy; Leukocyte Common Antigens; Male; Metabolic Syndrome; Middle Aged; Phenotype; Phosphodiesterase 5 Inhibitors; Stem Cells; Tadalafil; Treatment Outcome | 2011 |